Does a high arachidonic-acid-to-EPA ratio indicate glial activation?

An AA-to-EPA ratio is best understood as a peripheral fatty-acid-composition measure, not a brain-specific inflammatory test. This distinction is especially important when interpreting testing in an older adult, where a result should not be used to infer microglial or astrocyte status.

Lipid-mediator biology

• AA and EPA compete as substrates for eicosanoid-producing pathways. A higher AA:EPA ratio therefore indicates relatively greater AA availability for AA-derived mediators, some of which can be pro-inflammatory.
• In a 12-week randomized trial of 79 women, EPA-rich oil reduced erythrocyte AA:EPA from approximately 15:1 to 4:1 and was associated with lower UV-induced skin PGE₂ and 12-HETE, alongside relatively greater EPA-derived PGE₃ and 12-HEPE.
• Other EPA interventions increased EPA-derived HEPEs and 18-HEPE, a resolvin-E precursor. However, effects differ by tissue, stimulus, and mediator; omega-3 interventions have not consistently reduced general inflammatory markers or all AA-derived products.

Interpretation limits

• The ratio is a compartment-specific compositional marker—often measured in erythrocytes—not a validated stand-alone measure of generalized systemic inflammation. No clinically validated cutoff establishes inflammatory disease activity or predicts patient outcomes.
• It is not a direct test of glial activation: no human validation links peripheral AA:EPA values to TSPO-PET, CSF glial-associated markers, cellular assays, or histology, and there are no diagnostic thresholds, correlations, or accuracy data for this purpose.

Neuroimmune context

• Even TSPO-PET is an indirect and nonspecific neuroimmune signal. TSPO is expressed in microglia, reactive astrocytes, endothelial cells, and infiltrating myeloid cells, so it cannot identify a specific glial cell type or activation state.

Bottom line

• A high AA:EPA ratio can support the limited interpretation of a fatty-acid balance capable of favoring selected AA-derived lipid mediators; it cannot establish systemic inflammation, neuroinflammation, or activated glia.